Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin

Biotechnology Journal

Volumn 10, Issue 7, 2015, Pages 1067-1081

  Baik, Jong Youn ^a   Dahodwala, Hussain ^a   Oduah, Eziafa ^a   Talman, Lee ^a   Gemmill, Trent R ^a,b   Gasimli, Leyla ^c   Datta, Payel ^c   Yang, Bo ^d   Li, Guoyun ^d   Zhang, Fuming ^e   Li, Lingyun ^d   Linhardt, Robert J ^c,d,e   Campbell, Andrew M ^f   Gorfien, Stephen F ^f   Sharfstein, Susan T ^a  

^a SUNY POLYTECHNIC INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^d Rensselaer Polytechnic Institute   (United States)

^e RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^f Thermo Fisher Scientific   (United States)

Author keywords

CHO cells; Disaccharide analysis; Fed batch cultures; Glycosaminoglycans; Metabolic engineering

Indexed keywords

ANIMALS; BATCH CELL CULTURE; CELLS; CYTOLOGY; DRUG PRODUCTS; METABOLIC ENGINEERING; METABOLISM; POLYSACCHARIDES; PRODUCTIVITY;

ANTICOAGULANT ACTIVITIES; BIOPROCESS OPTIMIZATION; CHINESE HAMSTER OVARY CELLS; CHO CELL; DISACCHARIDE ANALYSIS; FED-BATCH CULTURES; GLYCOSAMINOGLYCANS; STIRRED TANK BIOREACTORS;

CELL ENGINEERING;

HEPARAN SULFATE; HEPARIN; ANTICOAGULANT AGENT;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BATCH REACTOR; BIOPROCESS; CELL DENSITY; CELL ENGINEERING; CHO CELL LINE; CONTROLLED STUDY; DRUG SYNTHESIS; FED BATCH CULTURE; FEMALE; GENE OVEREXPRESSION; METABOLIC ENGINEERING; NONHUMAN; NUTRIENT UPTAKE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; ANIMAL; BIOREACTOR; BIOSYNTHESIS; CRICETULUS; HAMSTER; METABOLISM;

ANIMALIA; CRICETULUS GRISEUS; SUS;

ANIMALS; ANTICOAGULANTS; BIOREACTORS; BIOSYNTHETIC PATHWAYS; CHO CELLS; CRICETINAE; CRICETULUS; HEPARIN; METABOLIC ENGINEERING;

EID: 84935706775     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400665     Document Type: Article

References (40)

1. Bhaskar, U., Sterner, E., Hickey, A. M., Onishi, A. et al., Engineering of routes to heparin and related polysaccharides. Appl. Microbiol. Biotechnol. 2012, 93, 1-16.
2. Linhardt, R. J., Heparin: Structure and activity J. Med. Chem. 2003, 46, 2551-2554.
3. Linhardt, R. J., Gunay, N. S., Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 1999, 25, 5-16.
4. Liu, H., Zhang, Z., Linhardt, R. J., Lessons learned from the contamination of heparin Nat. Prod. Rep. 2009, 26, 313-321.
5. Borsig, L., Heparin as an inhibitor of cancer progression, in: Zhang, L. (Ed.), Glycosaminoglycans in Development, Health and Disease, Vol.93, Elsevier 2010, pp. 335-349.
6. Casu, B., Naggi, A., Torri, G., Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 2010, 29, 442-452.
7. Maraveyas, A., Johnson, M. J., Xiao, Y. P., Noble, S., Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer Metastasis Rev. 2010, 29, 777-784.
8. Robert, F., The potential benefits of low-molecular-weight heparins in cancer patients. J. Hematol. Oncol. 2010, 3, DOI: 10.1186/1756-8722-3-3.
9. Yu, L. Y., Garg, H. G., Li, B., Linhardt, R. J. et al., Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. Curr. Cancer Drug Targets 2010, 10, 229-241.
10. Li, P. L., Sheng, J. Z., Liu, Y. H., Li, J. et al., Heparosan-derived heparan sulfate/heparin-like compounds: One kind of potential therapeutic agents. Med. Res. Rev. 2013, 33, 665-692.
11. Potdar, N., Gelbaya, T. A., Konje, J. C., Nardo, L. G., Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: A systematic review and meta-analysis. Hum. Reprod. Update 2013, 19, 674-684.
12. Seshadri, S., Sunkara, S. K., Khalaf, Y., El-Toukhy, T. et al., Effect of heparin on the outcome of IVF treatment: A systematic review and meta-analysis. Reprod. Biomed. Online 2012, 25, 572-584.
13. Shastri, M. D., Peterson, G. M., Stewart, N., Sohal, S. S. et al., Non-anticoagulant derivatives of heparin for the management of asthma: Distant dream or close reality? Expert Opin. Investig. Drugs 2014, 23, 357-373.
14. Yadav, V. K., Saraswat, M., Chhikara, N., Singh, S. et al., Heparin and heparin binding proteins: Potential relevance to reproductive physiology. Curr. Protein Pept. Sci. 2013, 14, 61-69.
15. Baik, J. Y., Gasimli, L., Yang, B., Datta, P. et al., Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin. Metab. Eng. 2012, 14, 81-90.
16. Baik, J. Y., Wang, C. L., Yang, B., Linhardt, R. J. et al., Toward a bioengineered heparin: Challenges and strategies for metabolic engineering of mammalian cells. Bioengineered 2012, 3, 227-231.
17. Chotigeat, W., Watanapokasin, Y., Mahler, S., Gray, P. P., Role of environmental conditions on the expression levels, glycoform pattern and levels of sialyltransferase for hFSH produced by recombinant CHO cells. Cytotechnology 1994, 15, 217-221.
18. Lin, A. A., Kimura, R., Miller, W. M., Production of tPA in recombinant CHO cells under oxygen-limited conditions. Biotechnol. Bioeng. 1993, 42, 339-350.
19. Kunkel, J. P., Jan, D. C. H., Jamieson, J. C., Butler, M., Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol. 1998, 62, 55-71.
20. Trummer, E., Fauland, K., Seidinger, S., Schriebl, K. et al., Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol. Bioeng. 2006, 94, 1033-1044.
21. Serrato, J. A., Palomares, L. A., Meneses-Acosta, A., Ramírez, O. T., Heterogeneous conditions in dissolved oxygen affect N-glycosylation but not productivity of a monoclonal antibody in hybridoma cultures. Biotechnol. Bioeng. 2004, 88, 176-188.
22. Hayter, P. M., Curling, E. M., Baines, A. J., Jenkins, N. et al., Glucose-limited chemostat culture of Chinese hamster ovary cells producing recombinant human interferon-gamma. Biotechnol. Bioeng. 1992, 39, 327-335.
23. Xie, L., Nyberg, G., Gu, X., Li, H. et al., Gamma-interferon production and quality in stoichiometric fed-batch cultures of Chinese hamster ovary (CHO) cells under serum-free conditions. Biotechnol. Bioeng. 1997, 56, 577-582.
24. Nyberg, G. B., Balcarcel, R. R., Follstad, B. D., Stephanopoulos, G. et al., Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol. Bioeng. 1999, 62, 336-347.
25. Takuma, S., Hirashima, C., Piret, J. M., Dependence on glucose limitation of the pCO2 influences on CHO cell growth, metabolism and IgG production. Biotechnol. Bioeng. 2007, 97, 1479-1488.
26. Wong, D. C. F., Wong, K. T. K., Goh, L. T., Heng, C. K. et al., Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol. Bioeng. 2005, 89, 164-177.
27. Volpi, N., Galeotti, F., Yang, B., Linhardt, R. J., Analysis of glycosaminoglycan-derived, precolumn, 2-aminoacridone-labeled disaccharides with LC-fluorescence and LC-MS detection. Nat. Protoc. 2014, 9, 541-558.
28. Yang, B., Chang, Y., Weyers, A. M., Sterner, E. et al., Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J. Chromatogr. A 2012, 1225, 91-98.
29. Atha, D., Lormeau, J.-C., Petitou, M., Rosenberg, R. et al., Contribution of monosaccharide residues in HP binding to antithrombin III. Biochemistry 1985, 24, 6723-6729.
30. Lindahl, U., Backstrom, G., Thunberg, L., Leder, I., Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of HP. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 6551-6555.
31. Li, G., Yang, B., Li, L., Zhang, F. et al., Analysis of 3-O-sulfo group-containing heparin tetrasaccharides in heparin by liquid chromatography-mass spectrometry. Anal. Biochem. 2014, 455, 3-9.
32. Wurm, F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004, 22, 1393-1398.
33. Zhang, H. F., Wang, H. B., Liu, M., Zhang, T. et al., Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody. Cytotechnology 2013, 65, 363-378.
34. Burky, J. E., Wesson, M. C., Young, A., Farnsworth, S. et al., Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng. 2007, 96, 281-293.
35. Shriver, Z., Raguram, S., Sasisekharan, R., Glycomics: A pathway to a class of new and improved therapeutics. Nat. Rev. Drug Discov. 2004, 3, 863-873.
36. National Research Council of the National Academies, Transforming Glycoscience: A Roadmap for the Future, The National Academies Press, Washington, DC 2012.
37. Dahodwala, H., Nowey, M., Mitina, T., Sharfstein, S., Effects of clonal variation on growth, metabolism, and productivity in response to trophic factor stimulation: A study of Chinese hamster ovary cells producing a recombinant monoclonal antibody. Cytotechnology 2012, 64, 27-41.
38. Carlsson, P., Kjellén, L., Heparin Biosynthesis, in: Lever, R., Mulloy, B., Page, C. P. (Eds.), Heparin - A Century of Progress, Springer Berlin Heidelberg 2012, pp. 23-41.
39. Shworak, N. W., Kobayashi, T., Agostini, A. D., Smits, N. C., Anticoagulant heparan sulfate: To not clot - or not?, in: Lijuan, Z. (Ed.), Progress in Molecular Biology and Translational Science, Academic Press 2010, pp. 153-178.
40. Thacker, B. E., Xu, D., Lawrence, R., Esko, J. D., Heparan sulfate 3-O-sulfation: A rare modification in search of a function. Matrix Biol. 2014, 35, 60-72.